BIRC2 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC2 status and adult T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BIRC3 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and adult T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CARD11 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CARD11 status and adult T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD79A is an inclusion eligibility criterion in 1 clinical trial for adult T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CD79A status and adult T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD79B is an inclusion eligibility criterion in 1 clinical trial for adult T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and adult T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NFKBIA is an inclusion eligibility criterion in 1 clinical trial for adult T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NFKBIA status and adult T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TNFAIP3 is an inclusion eligibility criterion in 1 clinical trial for adult T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TNFAIP3 status and adult T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].